The role of serum cryptococcal antigen screening for the early diagnosis of cryptococcosis in HIV-infected patients with different ranges of CD4 cell
IL-2 induced a very considerable rise in CD4 cell
count in both groups of patients, and yet there was no clinical benefit.
In addition, two months after the start of therapy and at least once every six months thereafter, patients visited the clinic for a medical evaluation, including CD4 cell
count, and were interviewed about their adherence to their medication.
The CD4 cell
count at baseline appeared to influence the amount of benefit seen with combined antiretroviral therapy.
Though the exact action of IND- 02 is not clear, the molecule prevents replication of HIV by protecting a crucial defence protein called APOBEC3G ( apolipoprotein B mRNA editing enzyme, catalytic polypeptide- like 3G), produced by CD4 cells
. APOBEC3G neutralises the virus.
Indeed there are emerging data that endorse the idea of starting antiretroviral therapy at CD4 cell
counts considerably higher than 350 cells/[mm.sup.3].
Effects of HIV-1 serostatus, HIV-1 RNA concentration, and CD4 cell
count on the incidence of malaria infection in a cohort of adults in rural Malawi.
At 72 weeks, there was no longer any significant difference in viral load, and there was a diminished, albeit still significant, difference in CD4 cell
*The CD4 cell
is one of the body's main lines of defence against infectious diseases.
Rapid ART start is especially important for people with very low CD4 cell
count, for whom the risk of death is high.
In 2016, seven years after initiation salvage therapy with DRV/r, 71.7% of patients had HIV RNA <50 copies/mL and their CD4 cell
counts increased by a mean of 353 cells/mm (3).
The introduction of ART has drastically changed the prognosis of HIV infected patients, in terms of decreasing mortality rate and decreasing incidences of opportunistic infections (OIs).The effect of ART is also well established for surrogate-markers such as the viral load and CD4 cell